Hisamitsu Pharmaceutical Overview
- Founded
-
1847
- Status
-
Public
- Employees
-
3,643
- Stock Symbol
-
4530
- Investments
-
2
- Share Price
-
$25.56
- (As of Wednesday Closing)
Hisamitsu Pharmaceutical General Information
Description
Hisamitsu Pharmaceutical Co Inc is a major pharmaceutical products manufacturer in Japan. The company collaborates with its subsidiaries and associates in operating its business across two segments, The Medical and Related Product segment and the Others segment. The Medical segment represents the company's foremost revenue generating operations. It markets drugs under the Salanpas, Salonsip, Lifecella, Mohrus and Keplat brands, which mainly serve topical medication needs with pain relief creams, gels, sprays, lotions and ointments. The Others segment refers to its miscellaneous businesses such as cable television broadcasting, internet connection, packing materials and insurance. Apart from its primary market in Japan, Hisamitsu has a reach across other regions like North America.
Contact Information
- 408 Tashiro Daikan-machi
- Tosu
- Saga, 841-0017
- Japan
Hisamitsu Pharmaceutical Stock Performance
(As of Wednesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $25.56 | $25.95 | $22.35 - $31.60 | $2.03B | 78.1M | 115K | $1.25 |
Hisamitsu Pharmaceutical Financials Summary
|
In Thousands, USD |
TTM 30-Nov-2022 | FY 2022 28-Feb-2022 | FY 2021 28-Feb-2021 | FY 2020 29-Feb-2020 |
|---|---|---|---|---|
| EV | 1,157,298 | 1,296,011 | 3,836,688 | 1,914,592 |
| Revenue | 967,556 | 1,077,838 | 1,080,721 | 1,293,214 |
| EBITDA | 153,740 | 148,390 | 268,591 | |
| Net Income | 100,003 | 86,609 | 87,300 | 171,466 |
| Total Assets | 2,427,557 | 2,620,219 | 2,812,691 | 2,843,673 |
| Total Debt | 8,914 | 21,283 | 15,027 | 16,420 |
Hisamitsu Pharmaceutical Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Hisamitsu Pharmaceutical Executive Team (2)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Kazuhide Nakatomi | Chief Executive Officer, Board Member and President | ||
| Nobuo Tsutsumi | Board Member & General Manager |
Hisamitsu Pharmaceutical Board Members (5)
| Name | Representing | Role | Since |
|---|---|---|---|
| 0000 00000000 | Hisamitsu Pharmaceutical | Board Member | 000 0000 |
| 00000000 00000000 | Hisamitsu Pharmaceutical | Chief Executive Officer, Board Member and President | 000 0000 |
| 00000 00000000 | Hisamitsu Pharmaceutical | Board Member & General Manager | 000 0000 |
| 0000000 00000000 | Hisamitsu Pharmaceutical | Board Member | 000 0000 |
| 00000000 00000 | Hisamitsu Pharmaceutical | Board Member | 000 0000 |
Hisamitsu Pharmaceutical Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Hisamitsu Pharmaceutical Investments & Acquisitions (2)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 0000 00000000 | 21-Sep-2021 | 00000 0000 | 000.00 | Biotechnology | |
| Noven Pharmaceuticals | 27-Aug-2009 | Merger/Acquisition | 00000 | Pharmaceuticals |
Hisamitsu Pharmaceutical Subsidiaries (1)
| Company Name | Industry | Location | Founded |
|---|---|---|---|
| 00000 000000000000 | Pharmaceuticals | Miami, FL | 0000 |
Hisamitsu Pharmaceutical ESG
Risk Overview
Risk Rating
Updated April, 07, 2023
33.04 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
00.00
Management
Management is related to actions taken to manage ESG issues
00.00
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
00 of 15,233
Rank
Percentile
Pharmaceuticals
Industry
00 of 866
Rank
Percentile
Pharmaceuticals
Subindustry
00 of 420
Rank
Percentile
